Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/05/019385
CTRI/2019/05/019385
Not yet recruiting
未知

Pharmaceutico-analytical study and randomized controlled clinical trial of modified mukhakantiprada lepa in vyanga

Sane guruji Arogya kendra0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Status
Not yet recruiting
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1\.Patient showing signs and symptoms of vyanga as per classical text like Niruja(painless),Mandala(round patch),Shyava(blotchy brown pigmentation) on face

Exclusion Criteria

  • •1\.Birth mark
  • •2\.Any known facial injuries with scares
  • •3\.Hormonal therapy and patient with systemic disorders.
  • •4\.Patients on any other medication for the same problem during the study
  • •5\.Pregnant ladies

Investigators

Similar Trials

Completed
Phase 2
A Clinical trial to Study the Effects of Two Drugs in patients of Diabetes Mellitus(type -II )Health Condition 1: E119- Type 2 diabetes mellitus without complications
CTRI/2018/09/015808ational Institute of Ayurveda Jaipur30
Completed
Phase 4
A study on pharmacokinetics (fate of drug in the body) of single oral dose of 15mg and 45 mg Primaquine in healthy human volunteers
CTRI/2011/06/001803I12
Not yet recruiting
Phase 1
Clinical study of Darvyadi Granules in Iron Deficiency Anaemia.Health Condition 1: D508- Other iron deficiency anemiasHealth Condition 2: D508- Other iron deficiency anemias
CTRI/2020/04/024459Parul University
Active, not recruiting
Phase 1
A study to compare the blood concentration of budesonide and the bronchodilatory effect after administration of the following study drugs: Budesonide-Salmeterol DPI capsule 75-25 µg, Budesonide-Salmeterol DPI capsule 75-12.5 µg, Budesonide-Salmeterol DPI capsule 75-6.25 µg delivered by the Axahaler® versus Serevent® Diskus® 50 µg + Pulmicort® Turbohaler® 100µg co-administration in asthmatic childreRegular Treatment of AsthmaMedDRA version: 20.0Level: LLTClassification code 10003560Term: Asthma NOSSystem Organ Class: 100000015470Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2017-003330-91-BGaboratoires SMB S.A.48
Not yet recruiting
Phase 2
Effect of Brahmighrta in the management of DementiaHealth Condition 1: F192- Other psychoactive substance dependence
CTRI/2022/11/047302Banaras Hindu University